Basaglar ® (insulin glargine) injection

100 units/mL

This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.

BASAGLAR® (insulin glargine injection): Transitioning From Insulin Degludec

Basaglar has not been studied in patients previously on IDeg. Therefore, if transitioning from IDeg to Basaglar, a different dose of Basaglar and concomitant therapies may be needed.

Transitioning From Insulin Degludec to Basaglar

Basaglar has not been studied in patients previously on IDeg.

Based on patient-level meta-analyses that were performed on 7 phase 3a trials that compared IDeg with IGlar (Table 1), a transition from IDeg to Basaglar may be made on a unit-to-unit basis. The dose of Basaglar may require up titration for

  • basal-bolus-treated T1DM patients, and

  • insulin-naive T2DM patients.1

Table 1. Daily Mean Dose of Insulin Glargine and Insulin Degludec at End of Trial1




Dose Difference

P Value


0.77 units/kg

0.68 units/kg




0.43 units/kg

0.39 units/kg




1.18 units/kg

1.22 units/kg



Abbreviations: IDeg = insulin degludec; IGlar = insulin glargine; NS = not significant; T1DMB/B = basal-bolus-treated patients with type 1 diabetes mellitus; T2DMB/B = basal-bolus-treated patients with type 2 diabetes mellitus; T2DMinsulin-naïve = insulin-naive patients with type 2 diabetes mellitus.

Changes in Insulin Regimen

Patients may be predisposed to hypoglycemia or hyperglycemia by changes in insulin

  • strength

  • manufacturer

  • type

  • injection site, or

  • method of administration.2

Insulin treatment changes should be made

  • under close medical supervision, and

  • with increased frequency of BG monitoring.2

In patients with T2DM, the amount and timing of short- or rapid-acting insulins and dosages of antihyperglycemic medications may need to be adjusted.2

Enclosed Prescribing Information

BASAGLAR® (insulin glargine injection), for subcutaneous use, Lilly


The published reference below is available by contacting 1-800-LillyRx (1-800-545-5979).

1. Vora J, Christensen T, Rana A, Bain SC. Insulin degludec versus insulin glargine in type 1 and type 2 diabetes mellitus: a meta-analysis of endpoints in phase 3a trials. Diabetes Ther. 2014;5(2):435-446.

2. Basaglar [package insert]. Indianapolis, IN: Eli Lilly and Company; 2019.


Basaglar = Basaglar® (insulin glargine injection) 100 units/mL

BG = blood glucose

IDeg = insulin degludec

IGlar = insulin glargine

T1DM = type 1 diabetes mellitus

T2DM = type 2 diabetes mellitus

Date of Last Review: January 07, 2020

Contact Lilly

Call Us

If you need information about a Lilly product or want to report an Adverse Event or Product Complaint, you may call us.

Available Mon – Friday, 9am-7pm (EST), excluding holidays

Or you can

Chat with us

Chat with us

Submit a Request

Visit Us @LillyMedical